PubMed · 11909895
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
S B Hutton. 2002. Improved antisaccade performance in schizophrenia with risperidone.. https://doi.org/10.1136/jnnp.72.4.429
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
This review examines the question--Do atypical antipsychotic medications improve psychosocial outcomes?--by examining studies that compared the effects of atypicals to conventional antipsychotics or to other atypical medications. The authors reviewed randomized clinical trials of atypical antipsychotic medication that included psychosocial variables as outcomes. Findings from 31 published studies on more than 12,000 individuals generally showed that atypical medications led to significant improvements in negative symptoms compared to conventional antipsychotics. Effects on global assessment of psychosocial functioning and on the quality of life were mixed with only about half the studies reporting significant improvements. Olanzapine yielded the best results on psychosocial functioning; remoxipride was found to yield few significant changes on these variables. This review provides evidence that some atypical antipsychotics may have direct effects on some of the psychosocial disabilities that result from serious mental illness.
Random-coefficient pattern-mixture models (RCPMMs) have been proposed for longitudinal data when drop-out is thought to be non-ignorable. An RCPMM is a random-effects model with summaries of drop-out time included among the regressors. The basis of every RCPMM is extrapolation. We review RCPMMs, describe various extrapolation strategies, and show how analyses may be simplified through multiple imputation. Using simulated and real data, we show that alternative RCPMMs that fit equally well may lead to very different estimates for parameters of interest. We also show that minor model misspecification can introduce biases that are quite large relative to standard errors, even in fairly small samples. For many scientific applications, where the form of the population model and nature of the drop-out are unknown, interval estimates from any single RCPMM may suffer from undercoverage because uncertainty about model specification is not taken into account.
Quetiapine (bis [2-(2-[4-(dibenzo[b,f][1,4]thiazepin-11-yl]ethoxy)ethanol]fumarate) is the most recent agent introduced on the drug market for the treatment of psychotic disorders. Two different analytical methods for the quality control of quetiapine in commercial formulations have been developed and compared: a spectrophotometric method and a capillary zone electrophoretic (CZE) method. The spectrophotometric assay was carried out measuring the absorbance at a wavelength of 246 nm. The CZE method used an uncoated fused-silica capillary and a pH 2.5, 50 mM phosphate buffer as the background electrolyte. The detection wavelength was 205 nm, the separation voltage was 15 kV, and a complete electrophoretic run lasts less than 2.5 min. Extraction of quetiapine from the commercial tablets consisted of a simple one-step treatment with a pH 2.5, 50 mM phosphate buffer. Linearity was observed in the 5-25 microg ml(-1) concentration range of quetiapine for the spectrophotometric method, and in the 5-50 microg ml(-1) concentration range for the electrophoretic method. Both methods gave satisfactory results in terms of repeatability and intermediate precision (RSD<1.9%). Also accuracy values were very good for both methods, the recovery being between 98.2 and 100.5%.